How to Reconstitute CJC-1295 + Ipamorelin Blend: Laboratory Reconstitution Protocol
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
How to Reconstitute CJC-1295 + Ipamorelin Blend: Laboratory Reconstitution Protocol
The CJC-1295 + Ipamorelin Blend (2mg/2mg per vial) combines CJC-1295 No DAC (GHRH-R agonist) and Ipamorelin (GHSR-1a agonist) co-lyophilised in a single 10mL sterile glass vial. This is the most commonly used dual GH axis blend in research settings due to ipamorelin's exceptional GHSR-1a selectivity, which produces clean, attributable receptor pharmacology data without the off-target corticotroph and lactotroph activity seen with GHRP-2 and GHRP-6.
Materials Required
- CJC-1295 + Ipamorelin Blend 2mg/2mg lyophilised vial
- Bacteriostatic water (BAC water) — 10mL vial
- 1mL sterile syringe with needle
- Alcohol swabs (70% isopropyl)
- Nitrile gloves
- Permanent marker for labelling
Pre-Reconstitution Preparation
Inspect the vial for intact lyophilised powder and unbroken seal. Allow to equilibrate to room temperature for 10 minutes. Both CJC-1295 No DAC and ipamorelin are freely soluble in BAC water — the blend reconstitutes as easily as either individual peptide and requires no special handling beyond standard aseptic technique.
Step-by-Step Reconstitution Protocol
Step 1 — Prepare workspace. Wipe work surface with 70% isopropyl alcohol. Allow to dry. Wear nitrile gloves throughout.
Step 2 — Swab both stoppers. Clean rubber stoppers on both vials with separate fresh alcohol swabs. Air dry 10 seconds each.
Step 3 — Draw 2mL of BAC water. Draw 2mL of bacteriostatic water into a sterile syringe.
Step 4 — Inject slowly along the vial wall. Direct BAC water slowly down the inner glass wall of the blend vial over 15 seconds. Do not inject directly onto the lyophilised blend powder.
Step 5 — Dissolve gently. Swirl gently for 20–30 seconds. Both peptides dissolve readily and the solution should be clear and colourless quickly. Do not shake or vortex.
Step 6 — Label. Record reconstitution date, concentrations of each component (1mg/mL each), and initials on the vial label.
Resulting Concentration
Adding 2mL BAC water to the 2mg/2mg blend vial yields a stock concentration of 1mg/mL CJC-1295 No DAC + 1mg/mL Ipamorelin (1000mcg/mL each). For synergistic GHRH-R/GHSR-1a GH axis studies in GH3 pituitary and somatotroph cell model preparations, working concentrations of 1nM–100nM of each peptide are prepared by serial dilution.
Concentration Reference Table
| BAC Water Added | CJC-1295 No DAC | Ipamorelin |
|---|---|---|
| 1mL | 2.0mg/mL | 2.0mg/mL |
| 2mL | 1.0mg/mL | 1.0mg/mL |
Storage Conditions and Stability
Store lyophilised blend at −20°C prior to reconstitution, protected from light and moisture. Once reconstituted, store at 2–8°C for up to 28 days. Both peptides maintain stability under standard refrigeration. Do not freeze reconstituted solution. CJC-1295 No DAC's four stabilising amino acid substitutions confer DPP-IV resistance, while ipamorelin's N-terminal Aib residue provides some protease resistance — the blend is stable in serum-containing media longer than native GHRH or sermorelin. Prepare single-use aliquots at −80°C for long-term storage.
Research Application Notes
The CJC-1295 + Ipamorelin blend is the preferred dual GH axis compound for mechanistically clean receptor pharmacology research because ipamorelin's GHSR-1a selectivity ensures that GHSR-1a-mediated Gq/calcium pathway responses can be attributed exclusively to GHSR-1a without confounding contributions from ACTH-releasing or prolactin-stimulating receptor systems. In comparative blend studies, CJC-1295 + Ipamorelin versus CJC-1295 + GHRP-2 in matched pituitary cell model systems quantifies the contribution of GHSR-1a selectivity to synergistic GH secretion profiles. Always run individual peptide controls (CJC-1295 No DAC alone and ipamorelin alone) alongside blend assays to establish the additive versus synergistic components of dual receptor activation. The Gs-cAMP (GHRH-R) and Gq-calcium (GHSR-1a) pathway co-activation can be dissected using pathway-selective inhibitors — H89 for PKA/Gs and YM-254890 for Gq — applied individually and in combination to blend-treated GH3 cell preparations. CJC-1295 + Ipamorelin Blend 2mg/2mg vials are available from Pinnacle Peptides, verified at ≥99% purity by HPLC and mass spectrometry.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
